Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.48 USD | +0.89% | -2.43% | +17.90% |
Sales 2024 * | 27.24M 34.64M | Sales 2025 * | 32.04M 40.73M | Capitalization | 750M 954M |
---|---|---|---|---|---|
Net income 2024 * | -40M -50.86M | Net income 2025 * | -73M -92.82M | EV / Sales 2024 * | 24.2 x |
Net cash position 2024 * | 91.87M 117M | Net cash position 2025 * | 84.26M 107M | EV / Sales 2025 * | 20.8 x |
P/E ratio 2024 * |
-52.5
x | P/E ratio 2025 * |
-30.6
x | Employees | 109 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
Latest transcript on Silence Therapeutics plc
1 day | +0.89% | ||
1 week | -2.43% | ||
Current month | -2.43% | ||
1 month | -10.76% | ||
3 months | -19.97% | ||
6 months | +41.24% | ||
Current year | +17.90% |
Managers | Title | Age | Since |
---|---|---|---|
Craig Tooman
CEO | Chief Executive Officer | 58 | 21-01-05 |
Director of Finance/CFO | 52 | 21-03-31 | |
Curtis Rambaran
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven Romano
CTO | Chief Tech/Sci/R&D Officer | 64 | 19-07-28 |
David Lemus
BRD | Director/Board Member | 61 | 18-06-20 |
Iain Ross
CHM | Chairman | 71 | 04-07-01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 20.48 | +0.89% | 71,107 |
24-06-06 | 20.3 | +1.50% | 155,231 |
24-06-05 | 20 | +0.81% | 82,197 |
24-06-04 | 19.84 | -3.83% | 86,871 |
24-06-03 | 20.63 | -1.72% | 134,385 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
- Stock Market
- Equities
- SLN Stock